This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
osteoporosis
Osteoporosis
Skeletal disease of low bone density and microarchitectural deterioration → fragility fractures. Driven by estrogen deficiency and osteoclast-osteoblast uncoupling; bisphosphonates, denosumab (RANKL inhibitor), and romosozumab (anti-sclerostin) reduce fracture risk.
Entry Metadata
| Field | Value |
|---|---|
| ID | osteoporosis |
| Name | Osteoporosis |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Kanis JA, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3-44. · PubMed 30324412
- Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532-1543. · PubMed 27641143
- Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-765. · PubMed 19671655